Table 4. Correlation coefficients between CEC or AREA and various parameters at baseline and follow-up.
| Cholesterol efflux capacity |
Arylesterase acitivity |
|||||
|---|---|---|---|---|---|---|
| Baseline | Follow-up | Net change | Baseline | Follow-up | Net change | |
| Age | −0.122 (84) | −0.110 (84) | NA | −0.268* (72) | −0.310** (72) | NA |
| −0.071 (61) | −0.136 (61) | −0.301* (52) | 0.413 (52) | |||
| −0.116 (69) | −0.150 (69) | −0.354** (60) | −0.390** (60) | |||
| Peak VO2 | 0.111 (75) | 0.122 (84) | 0.049 (69) | 0.339** (65) | 0.380** (60) | −0.012 (60) |
| 0.261 (54) | 0.197 (49) | 0.171 (49) | 0.357* (47) | 0.428** (43) | 0.044 (43) | |
| 0.085 (69) | 0.122 (69) | 0.049 (69) | 0.331* (60) | 0.380** (60) | −0.012 (60) | |
| HDL-C | 0.346** (84) | 0.231* (84) | 0.305** (84) | 0.194 (72) | 0.198 (72) | 0.339** (72) |
| 0.383** (61) | 0.363** (61) | 0.261* (61) | 0.170 (52) | 0.162 (52) | 0.345* (52) | |
| 0.334** (69) | 0.228 (69) | 0.247* (69) | 0.249 (60) | 0.193 (60) | 0.312* (60) | |
| Apo A1 | 0.357** (84) | 0.227* (84) | 0.331** (84) | 0.376** (72) | 0.281* (72) | 0.412*** (72) |
| 0.390** (61) | 0.354** (61) | 0.344** (61) | 0.329* (52) | 0.224 (52) | 0.330* (52) | |
| 0.312** (69) | 0.262* (69) | 0.326** (69 | 0.441*** (60) | 0.248 (60) | 0.379** (60) | |
| TG | 0.152 (84) | 0.171 (84) | 0.020 (84) | 0.179 (72) | 0.331** (72) | 0.113 (72) |
| 0.155 (61) | 0.145 (61) | 0.041 (61) | 0.142 (52) | 0.434** (52) | 0.031 (52) | |
| 0.128 (69) | 0.340** (69) | 0.112 (69) | 0.202 (60) | 0.413** (60) | 0.154 (60) | |
| MDA-LDL | 0.168 (84) | 0.126 (84) | 0.004 (80) | 0.003 (70) | 0.065 (72) | 0.141 (70) |
| 0.254* (61) | 0.142 (60) | 0.113 (60) | 0.166 (52) | 0.121 (52) | 0.214 (52) | |
| 0.110 (66) | 0.229 (69) | −0.086 (66) | 0.117 (58) | 0.133 (60) | 0.210 (58) | |
| BNP | 0.113 (84) | −0.137 (78) | −0.144 (78) | −0.046 (72) | −0.099 (66) | −0.206 (66) |
| 0.096 (61) | −0.137 (58) | −0.215 (58) | −0.022 (52) | −0.217 (49) | −0.090 (49) | |
| 0.135 (69) | −0.250* (64) | −0.207 (64) | −0.040 (60) | −0.195 (55) | −0.297* (55) | |
| eGFR | 0.235* (84) | 0.159 (84) | 0.103 (84) | 0.106 (72) | 0.153 (72) | −0.070 (72) |
| 0.190 (61) | 0.180 (61) | 0.025 (61) | 0.035 (52) | 0.185 (52) | −0.124 (52) | |
| 0.258 (69) | 0.215 (69) | 0.021 (69) | 0.178 (60) | 0.184 (60) | −0.144 (60) | |
| hsCRP | −0.033 (84) | −0.036 (84) | −0.085 (84) | −0.256* (72) | −0.062 (72) | −0.150 (72) |
| −0.134 (61) | −0.107 (61) | −0.024 (61) | −0.292* (52) | −0.075 (52) | −0.040 (52) | |
| −0.035 (69) | −0.061 (69) | −0.173 (69) | −0.236 (60) | −0.074 (60) | −0.239 (60) | |
Data are expressed as Spearman's Rho between the levels at baseline or follow-up and those counterparts, and between the values of net change and those counterparts. The upper, middle, and lower figures show whole patients, patients who did not take lipid-lowering drugs at baseline, and patients that completed the CR program, respectively. The number in parenthesis indicates actual number of analyzed cases. Seven samples at baseline were collected in a fasting-state at the beginning of the CR. The others were collected immediately before the emergency coronary angiography on admission. *p < 0.05, **p < 0.01, ***p < 0.001. N/A= not available. Abbreviations as in text.